Sujata Lalla-Reddy, MD
Infectious Disease · Fountain Valley, CANPI 1891711909
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,462 of the $57,291 with a category attached, or 74.1%. Gilead accounts for 85.3% of it on its own, with 35 other manufacturers making up the rest. Among infectious disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 546 payments — averaging $104.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$49K
- Viiv Healthcare Company$3K
- Merck$726
- Johnson & Johnson$725
- AbbVie$518
- Novo Nordisk$435
- plus $3K from 30 others
Across 19 payments — averaging $2757.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$26K
- Merck$21K
- GSK$3K
- Akebia Therapeutics Inc$2K
- Pfizer$240
What the payments were for
- Consulting fees$1,0402%
- Speaking & faculty fees$42,46274%
- Travel & lodging$1,4973%
- Food & beverage$12,05121%
- Education$2410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 184 | $48,843 |
| Viiv Healthcare Company | 105 | $2,640 |
| Merck | 43 | $726 |
| Johnson & Johnson(2 entities) | 40 | $725 |
| AbbVie(2 entities) | 27 | $518 |
| Novo Nordisk | 16 | $435 |
| Lilly USA, LLC | 14 | $389 |
| Cipla USA Inc. | 2 | $292 |
| EMD Serono, Inc. | 15 | $285 |
| Napo Pharmaceuticals Inc | 15 | $265 |
| Insmed, Inc. | 9 | $208 |
| Janssen Scientific Affairs, LLC | 5 | $205 |
| Paratek Pharmaceuticals, Inc. | 9 | $202 |
| Janssen Products, LP | 2 | $200 |
| AstraZeneca | 3 | $160 |
| Boehringer Ingelheim | 6 | $124 |
| Pfizer | 7 | $107 |
| Theratechnologies Inc. | 4 | $101 |
| Cumberland Pharmaceuticals, Inc. | 6 | $95 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $94 |
| Melinta Therapeutics, LLC | 5 | $90 |
| GSK | 3 | $80 |
| Amarin Pharma, Inc. | 4 | $75 |
| Exact Sciences | 3 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $67 |
| Merz North America, Inc. | 1 | $66 |
| Medtronic(2 entities) | 2 | $61 |
| Smith+Nephew | 2 | $38 |
| Antares Pharma, Inc. | 2 | $36 |
| Shionogi Inc | 1 | $24 |
| Phadia US Inc. | 1 | $18 |
| Vyera Pharmaceuticals, LLC | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Amgen | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,291 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 57 | $255,915 |
| EliquisApixaban | 195 | $53,139 |
| EntrestoSacubitril/Valsartan | 46 | $15,568 |
| JanuviaSitagliptin Phosphate | 35 | $14,833 |
| XareltoRivaroxaban | 24 | $14,817 |
| MounjaroTirzepatide | 14 | $14,040 |
| ErtapenemErtapenem Sodium | 30 | $13,844 |
| Budesonide | 33 | $6,376 |
| JardianceEmpagliflozin | 13 | $4,467 |
| SynjardyEmpagliflozin/Metformin Hcl | 16 | $4,295 |
| Atorvastatin Calcium | 226 | $3,232 |
| Enoxaparin Sodium | 35 | $3,043 |
| Megestrol Acetate | 33 | $2,998 |
| Meropenem | 18 | $2,994 |
| VascepaIcosapent Ethyl | 15 | $2,701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $48,843 | $255,91557 claims |
| PfizerEliquis | $107 | $53,139195 claims |
| MerckJanuvia | $726 | $14,83335 claims |
| Johnson & JohnsonXarelto | $725 | $14,81724 claims |
| Lilly USA, LLCMounjaro | $389 | $14,04014 claims |
| Boehringer IngelheimJardiance, Synjardy | $124 | $8,76329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 856 infectious disease providers in California.
Other infectious disease in Fountain Valley
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
- Franco FelizartaBakersfield$440K
- Shawn HasslerSan Francisco$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.